BIO Asia–Taiwan 2026 亞洲生技大會

BIO Asia–Taiwan 2026 亞洲生技大會

≡

MEDIA

​BIO Asia–Taiwan 2025 Concludes Successfully

BIO Asia–Taiwan 2025 Concludes Successfully
Exhibition Features 19 National Delegations, 850 Exhibitors, 2,200 Booths, and Nearly 140,000 Visits from 50 Countries
 
28 July, 2025
Centered on the theme Next Wave of Biotech Opportunities, the BIO Asia–Taiwan 2025 convention concluded successfully on July 27 at the Taipei Nangang Exhibition Center, TaiNEX 1, after a four-day run (July 23–27). The exhibition featured 23 exhibition zones covering the entire biotech value chain, bringing together delegates from 19 countries, 850 exhibitors, and more than 2,200 booths, and attracting nearly 140,000 visits from biotech professionals representing 50 countries. The conference segment focused on innovation, investment, and regional cooperation, and was successful in facilitating progress in cross-border regulatory harmonization, multinational clinical trials, and global investment, with estimated potential business opportunities worth [USD] billions.
 
BIO Asia–Taiwan Chair Johnsee Lee noted that over 700 international experts attended, with particularly strong participation from Australia (24 companies) as well as Japan, the US, and Canada.
 
For the first time, the Regional Collaboration Forums included separate forums from more than 10 countries, culminating in the launch of the Asia Pacific Regional Biotech Cooperation Working Group, intended to serve as an ongoing cross-border dialogue platform, especially benefiting developing countries in Southeast Asia.
 
The second annual BIO Asia Award honored individuals or organizations for outstanding contributions to the Asia-Pacific biotech sector. This year’s recipients were Raul V. Destura of the Philippines, recognized for his work in advancing infectious disease diagnostics in Southeast Asia and other developing countries; and Academician Chi-Huey Wong of Taiwan, recognized for his outstanding contributions to scientific innovation and its applications. Last year’s winner George Hara of Japan was in attendance and gave a presentation.
 
The number of business partnering meetings powered by the renowned Bio Partnering platform increased by 15% from last year, with around 8,800 meeting invitations sent. The Taiwan External Trade Development Council also hosted its first medical device, healthcare, and beauty products matchmaking event at the conference, expected to generate over US$300 million in business.
 
The Investment Summit, which attracted prominent global venture capital firms including Illumina Ventures and Syncona, was the stage for 30 high-potential startups to showcase innovations in oncology, cell therapy, and novel drug delivery, paving the way for future M&A and licensing deals.
 
The Innovation Forum highlighted cutting-edge topics including AI-driven drug development, cell therapy and CDMO services, smart healthcare, GLP-1 drugs for cardiovascular disease, weight loss and diabetes management, and antibody-drug conjugates (ADCs).
 
In addition to the main conference, satellite events were active and diverse, and included the National Biotechnology Research Park Demo Day and the TMU×BE×SCHS Demo Day, Alzheimer’s and cancer treatment forums, Pharmacopeia standards discussions, and a next-generation probiotics forum.
 
Looking to 2026, BIO Asia–Taiwan Chair Johnsee Lee has set his sights on the event breaking new records, adding agricultural biotech and green technology exhibition zones, expanding satellite activities, and deepening international alliances toward the vision of a Healthy Asia.